Evaluation of a novel antigen-enhanced, anti-idiotypic antibody vaccine strategy
Ended Project Grant Awarded Last action
- Award ID
- R21AI143505
- Recipient
-
Neovaxsyn Inc. UEI EHMTBALCKFE8
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $593,686
Award facts
- Assistance listing
- 93.855 Allergy and Infectious Diseases Research
- Completion date
- Originally
- Funding
-
- $524,124.00 Federal
- $69,562.00 Non-federal
- Place of performance
- Ames, IA 50014, USA
Award details come from USAspending.gov.
Transactions
| Action | Federal | Non-federal | Date |
|---|---|---|---|
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $40,449 | $0 | |
| Amendment | $29,113 | $0 | |
| Amendment | $40,449 | $40,449 | |
| Amendment | $29,113 | $29,113 | |
| Amendment | $210,000 | $0 | |
| Original award | $175,000 | $0 |
Quick answers
Who received award R21AI143505?
R21AI143505 was awarded to Neovaxsyn Inc. by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on December 19, 2018.
How much is award R21AI143505 worth?
$593,686 has been obligated on R21AI143505: $524,124 in federal funding and $69,562 in non-federal funding.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award